Literature DB >> 16413071

Mutation of Thr466 in SHP2 abolishes its phosphatase activity, but provides a new substrate-trapping mutant.

Rebecca Merritt1, Michael J Hayman, Yehenew M Agazie.   

Abstract

Most classical phosphotyrosyl phosphatases (PTPs), including the Src homology phosphotyrosyl phosphatase 2 (SHP2) possess a Thr or a Ser residue immediately C-terminal to the invariant Arg in the active site consensus motif (H/V-C-X5-R-S/T), also known as the "signature motif". SHP2 has a Thr (Thr466) at this position, but its importance in catalysis has not been investigated. By employing site-directed mutagenesis, phosphatase assays and substrate-trapping studies, we demonstrate that Thr466 is critical for the catalytic activity of SHP2. Its mutation to Ala abolishes phosphatase activity, but provides a new substrate-trapping mutant. We further show that the nucleophilic Cys459 is not involved in substrate trapping by Thr466Ala-SHP2 (T/A-SHP2). Mutation of Thr466 does not cause significant structural changes in the active site as revealed by the trapping of the epidermal growth factor receptor (EGFR), the physiological substrate of SHP2, and by orthovanadate competition experiments. Based on these results and previous other works, we propose that the role of Thr466 in the catalytic process of SHP2 could be stabilizing the sulfhydryl group of Cys459 in its reduced state, a state that enables nucleophilic attack on the phosphate moiety of the substrate. The T/A-SHP2 harbors a single mutation and specifically interacts with the EGFR. Since the nucleophilic Cys459 and the proton donor Asp425 are intact in the T/A-SAHP2, it offers an excellent starting material for solving the structure of SHP2 in complex with its physiological substrate.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16413071     DOI: 10.1016/j.bbamcr.2005.11.013

Source DB:  PubMed          Journal:  Biochim Biophys Acta        ISSN: 0006-3002


  8 in total

Review 1.  Cellular biochemistry methods for investigating protein tyrosine phosphatases.

Authors:  Stephanie M Stanford; Vanessa Ahmed; Amy M Barrios; Nunzio Bottini
Journal:  Antioxid Redox Signal       Date:  2014-02-25       Impact factor: 8.401

2.  Loss of tyrosine phosphatase-dependent inhibition promotes activation of tyrosine kinase c-Src in detached pancreatic cells.

Authors:  Sarah F Connelly; Beth A Isley; Cheryl H Baker; Gary E Gallick; Justin M Summy
Journal:  Mol Carcinog       Date:  2010-12       Impact factor: 4.784

3.  HDAC Inhibitor-Induced Mitotic Arrest Is Mediated by Eg5/KIF11 Acetylation.

Authors:  Dhanusha A Nalawansha; Inosha D Gomes; Magdalene K Wambua; Mary Kay H Pflum
Journal:  Cell Chem Biol       Date:  2017-04-06       Impact factor: 8.116

4.  New approaches to prevent LEOPARD syndrome-associated cardiac hypertrophy by specifically targeting Shp2-dependent signaling.

Authors:  Christine Schramm; Michelle A Edwards; Maike Krenz
Journal:  J Biol Chem       Date:  2013-05-14       Impact factor: 5.157

5.  Molecular mechanism for SHP2 in promoting HER2-induced signaling and transformation.

Authors:  Xiangdong Zhou; Yehenew M Agazie
Journal:  J Biol Chem       Date:  2009-03-04       Impact factor: 5.157

6.  Protein-protein interaction between caveolin-1 and SHP-2 is dependent on the N-SH2 domain of SHP-2.

Authors:  Hyunju Park; Keun Jae Ahn; Jihee Lee Kang; Youn-Hee Choi
Journal:  BMB Rep       Date:  2015-03       Impact factor: 4.778

7.  WDR1 is a novel EYA3 substrate and its dephosphorylation induces modifications of the cellular actin cytoskeleton.

Authors:  Mihaela Mentel; Aura E Ionescu; Ioana Puscalau-Girtu; Martin S Helm; Rodica A Badea; Silvio O Rizzoli; Stefan E Szedlacsek
Journal:  Sci Rep       Date:  2018-02-13       Impact factor: 4.379

8.  Dietary quercetin potentiates the antiproliferative effect of interferon-α in hepatocellular carcinoma cells through activation of JAK/STAT pathway signaling by inhibition of SHP2 phosphatase.

Authors:  Ighodaro Igbe; Xiao-Fei Shen; Wei Jiao; Zhe Qiang; Teng Deng; Sheng Li; Wan-Li Liu; Han-Wei Liu; Guo-Lin Zhang; Fei Wang
Journal:  Oncotarget       Date:  2017-11-20
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.